The azole antifungals act by inhibiting lanosterol 14-alpha-demethylase, a cytochrome P450 (CYP) enzyme. In fungi this enzyme is encoded by a gene designated ERG11 (ergosterol biosynthesis gene 11), and the enzyme itself is classified as CYP51 (cytochrome P450 sterol 14-alpha-demethylase). This ERG11-encoded CYP51 enzyme catalyzes a key step in ergosterol biosynthesis, and its inhibition depletes the fungal membrane of functional ergosterol while causing accumulation of toxic methylated sterol intermediates. The azoles are the most widely prescribed class of antifungal agents and include drugs with vastly different pharmacokinetic profiles, spectra of activity, and drug interaction liabilities.
The Ergosterol Biosynthesis Pathway. Ergosterol biosynthesis begins with acetyl-CoA and proceeds through the mevalonate pathway to squalene, which is converted by squalene epoxidase (the target of allylamines such as terbinafine) to lanosterol. From lanosterol, the fungal-specific pathway diverges from the mammalian cholesterol pathway at the point of CYP51 action. Fungal CYP51 (encoded by ERG11) catalyzes the oxidative removal of the 14-alpha-methyl group from lanosterol, producing 4,4-dimethylcholesta-8,14,24-trienol, a required intermediate on the route to ergosterol. Subsequent steps involving delta-8 to delta-7 isomerase, C-5 sterol desaturase (encoded by ERG3), and other enzymes ultimately yield ergosterol. Azole inhibition of CYP51 blocks this pathway at the lanosterol demethylation step, causing two simultaneous consequences: depletion of ergosterol, which is essential for normal membrane fluidity and enzyme function, and accumulation of 14-alpha-methylfecosterol and other toxic sterol intermediates that disrupt membrane structure and function.1
Mechanism of CYP51 Inhibition. All clinically used azoles share a common pharmacophoric core: a triazole or imidazole nitrogen atom that coordinates directly with the heme iron of the CYP51 active site, displacing the water molecule that normally occupies that position and that is essential for the oxidative catalytic cycle. This coordination is highly specific for fungal CYP51 relative to mammalian CYP51 (which participates in cholesterol biosynthesis) because of differences in the active site architecture between fungal and mammalian enzymes. The azole side chains extending from the triazole core make additional hydrophobic contacts with residues lining the CYP51 active site channel and determine selectivity, potency, and resistance susceptibility. Triazoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) are preferred over imidazoles (clotrimazole, miconazole, ketoconazole) for systemic use because triazoles have greater selectivity for fungal CYP51 over mammalian CYP enzymes and a safer systemic toxicity profile.12
Fungistatic vs. Fungicidal Activity. The azoles are predominantly fungistatic rather than fungicidal against most target organisms. Ergosterol depletion impairs fungal growth and replication but does not reliably cause rapid cell death, in contrast to the polyenes which form membrane pores and kill cells directly. The fungistatic nature of azoles has several clinical implications. First, azole therapy requires an intact host immune system to eliminate residual fungal cells that survive treatment; patients with profound immunosuppression may fail azole therapy despite achieving therapeutic drug concentrations. Second, fungistatic drugs carry a higher risk of selecting resistant mutants during prolonged courses because surviving cells continue to replicate. Third, azoles are not appropriate as primary monotherapy for conditions requiring rapid fungicidal activity, such as cryptococcal meningitis induction or candidemia in immunocompromised hosts, where polyenes or echinocandins with superior fungicidal kinetics are preferred.2
Cross-Reactivity with Mammalian CYP Enzymes. Because the triazole nitrogen that coordinates fungal CYP51 heme iron is structurally similar to the coordination site for mammalian hepatic CYP enzymes, azoles inhibit human CYP enzymes to varying degrees depending on the specific compound. This is the mechanistic basis for the extensive and clinically significant drug-drug interactions that characterize the azole class. The relevant human CYP enzymes include CYP3A4 (metabolizes the majority of clinically used drugs), CYP2C9 (metabolizes warfarin, phenytoin, sulfonylureas), and CYP2C19 (metabolizes proton pump inhibitors, clopidogrel, some antidepressants). The degree of human CYP inhibition differs substantially among azoles: fluconazole is a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4; itraconazole is a potent inhibitor of CYP3A4; voriconazole inhibits CYP2C9, CYP2C19, and CYP3A4. Understanding which CYP enzymes each azole inhibits and the magnitude of inhibition is essential for safe prescribing in patients receiving multiple medications.3
Azoles inhibit fungal CYP51 (lanosterol 14-alpha-demethylase, encoded by ERG11) by coordinating the heme iron of the enzyme active site. This blocks ergosterol synthesis and causes accumulation of toxic 14-alpha-methyl sterol intermediates. The result is fungistatic activity against most yeasts and molds. Cross-inhibition of mammalian CYP enzymes (CYP3A4, CYP2C9, CYP2C19) by the same azole nitrogen is the mechanistic basis for extensive drug-drug interactions that vary in magnitude among individual azole agents.
Fluconazole is the most widely used antifungal agent globally and the prototypical triazole. Its pharmacokinetic profile is uniquely favorable among the azoles: near-complete oral bioavailability, excellent penetration into all body compartments including the central nervous system, predictable linear pharmacokinetics, and renal elimination that allows straightforward dose adjustment. These properties have made fluconazole the cornerstone of both treatment and prophylaxis for many common fungal infections, though its narrow spectrum and the emergence of resistance in certain Candida species impose important limitations on its use.
Absorption and Bioavailability. Fluconazole is available in both oral and intravenous (IV) formulations, and its oral bioavailability is approximately 90%, one of the highest of any antifungal agent. Absorption is not significantly affected by gastric acid, food, or gastric motility, making it highly reliable in patients with altered gastrointestinal (GI) function including those receiving proton pump inhibitors (PPIs), those with gastroparesis, or those who have undergone GI surgery. This characteristic distinguishes fluconazole sharply from itraconazole capsules, whose absorption is highly pH-dependent and variable. The IV formulation is used when oral administration is not feasible (e.g., nil by mouth status, severe mucositis), but given the near-complete oral bioavailability, IV-to-oral conversion at equivalent doses is appropriate and recommended for cost containment and patient convenience as soon as oral administration is possible.4
Distribution and Tissue Penetration. Fluconazole has a large volume of distribution (approximately 0.7 L/kg) and distributes extensively into tissues, body fluids, and the central nervous system (CNS). Cerebrospinal fluid (CSF) concentrations reach approximately 60 to 80% of plasma concentrations, which is substantially higher than any other available azole and makes fluconazole uniquely valuable for CNS fungal infections. Protein binding is low (approximately 12%), contributing to the high free drug fraction available for distribution. Saliva, sputum, urine, and vaginal secretions all achieve drug concentrations at or near plasma levels, which accounts for the efficacy of fluconazole for superficial mucosal infections such as oropharyngeal candidiasis and vaginal candidiasis with a relatively short course of treatment.4
Metabolism and Elimination. Unlike most other azoles, fluconazole is predominantly eliminated unchanged by the kidneys, with approximately 80% of a dose excreted as intact drug in the urine. Hepatic metabolism accounts for only about 10% of elimination. This renal elimination route requires dose adjustment in patients with renal impairment: the standard fluconazole dose should be reduced by 50% when the creatinine clearance (CrCl) falls below 50 mL/min, and supplemental doses should be given after hemodialysis sessions because dialysis removes approximately half the drug from the body. The elimination half-life is approximately 30 hours in patients with normal renal function, allowing once-daily dosing for most indications. Because fluconazole is minimally metabolized by CYP3A4 (cytochrome P450 3A4) itself, its pharmacokinetics are not significantly affected by inducers or inhibitors of that enzyme, in contrast to itraconazole and voriconazole whose concentrations are highly sensitive to CYP3A4 modulation.4
Antifungal Spectrum. Fluconazole has activity against most Candida species, Cryptococcus neoformans and Cryptococcus gattii, and the dimorphic fungi causing endemic mycoses (Histoplasma capsulatum, Coccidioides immitis). It does not have clinically meaningful activity against Aspergillus species, the Mucorales (mucormycosis agents), or most other molds. Among Candida species, susceptibility is not uniform: Candida albicans, Candida tropicalis, and Candida parapsilosis are generally susceptible; Candida glabrata (now reclassified as Nakaseomyces glabrata) frequently shows reduced susceptibility or frank resistance due to upregulation of efflux pumps; and Candida krusei (now Pichia kudriavzevii) has intrinsic resistance to fluconazole. Species identification is therefore mandatory before relying on fluconazole for candidiasis treatment, and susceptibility testing should guide therapy for non-albicans species.56
Clinical Indications and Dosing. Fluconazole is the drug of choice for oropharyngeal and esophageal candidiasis (200 mg loading dose, then 100 to 200 mg daily for 14 to 21 days for esophageal disease), uncomplicated vulvovaginal candidiasis (single dose 150 mg orally), and consolidation and maintenance therapy for cryptococcal meningitis following amphotericin B induction (400 mg daily for consolidation, then 200 mg daily for maintenance until immune reconstitution). Fluconazole is also used for step-down therapy in stable patients with candidemia caused by susceptible species after initial echinocandin therapy, and for antifungal prophylaxis in high-risk patients (hematopoietic stem cell transplant recipients, high-risk liver transplant recipients, and patients with prolonged neutropenia in settings with high local rates of fluconazole-susceptible Candida infections).56
Oropharyngeal candidiasis: 200 mg day 1, then 100 mg daily ×7–14 days. Esophageal candidiasis: 200–400 mg daily ×14–21 days. Vulvovaginal candidiasis (uncomplicated): 150 mg single dose. Cryptococcal meningitis consolidation: 400 mg daily ×8 weeks. Cryptococcal meningitis maintenance: 200 mg daily until CD4 >200 cells/mm³ for ≥6 months on ART. Candidemia step-down: 400–800 mg daily (after echinocandin induction, susceptible species only). Renal dose adjustment: reduce dose 50% if CrCl <50 mL/min; supplement after hemodialysis.
Itraconazole presents one of the most complex pharmacokinetic profiles of any oral antifungal agent. Its two oral formulations (capsules and oral solution) behave so differently that they should be considered pharmacologically distinct agents for practical purposes. Understanding the absorption requirements, food and pH effects, and the necessity of therapeutic drug monitoring (TDM) is essential for safe and effective use of itraconazole in clinical practice.
Formulations and Absorption Mechanism. Itraconazole is a highly lipophilic compound with very low aqueous solubility. The capsule formulation contains itraconazole coated onto sugar spheres; dissolution and absorption require an acidic gastric environment and the presence of food to stimulate acid secretion and bile release, which facilitate drug solubilization. Under optimal conditions (with a full meal and normal gastric acidity), capsule bioavailability reaches approximately 55%. However, in patients receiving proton pump inhibitors (PPIs), acid-reducing agents such as histamine type-2 receptor antagonists (H2RAs), antacids, or those with achlorhydria, gastric pH rises and capsule absorption falls dramatically, sometimes to near zero. The oral solution formulation uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle, which dramatically improves absorption. The oral solution should be taken on an empty stomach (fasting) rather than with food, and achieves bioavailability of approximately 60% that is far less affected by gastric pH, making it the preferred oral formulation for most systemic indications. The oral solution also allows flexible dosing and is more suitable for patients who cannot swallow capsules.7
Distribution and Tissue Accumulation. Itraconazole has an extremely large volume of distribution (approximately 11 L/kg), reflecting extensive binding to plasma proteins (approximately 99.8% bound, predominantly to albumin) and massive accumulation in highly lipophilic tissues including skin, nails, lungs, liver, and adipose tissue. Tissue concentrations in these compartments exceed plasma concentrations by factors of 10 to 100 or more, which is clinically relevant because plasma concentrations underestimate tissue exposure. Itraconazole does not penetrate well into the central nervous system (CNS) or cerebrospinal fluid (CSF) due to its high lipophilicity and extensive protein binding, making it unsuitable for the treatment of CNS fungal infections. Similarly, aqueous humor, saliva, and urine concentrations are low, limiting utility for infections at these sites. The extensive tissue accumulation gives itraconazole a prolonged terminal elimination half-life of 24 to 42 hours after short courses, which extends further with prolonged administration as tissue compartments equilibrate.7
Metabolism and Drug Interactions Affecting Itraconazole Levels. Itraconazole is extensively metabolized by hepatic CYP3A4 (cytochrome P450 3A4) to numerous metabolites, of which hydroxy-itraconazole is the principal active metabolite with antifungal activity comparable to the parent compound. Because itraconazole is both a substrate of CYP3A4 and a potent inhibitor of CYP3A4, its concentration in plasma is highly sensitive to co-administered CYP3A4 inducers and inhibitors, and it simultaneously affects the plasma concentrations of many co-administered drugs. Strong CYP3A4 inducers (rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, efavirenz, nevirapine) dramatically reduce itraconazole plasma concentrations, sometimes to subtherapeutic levels; concurrent use of rifampin with itraconazole is essentially contraindicated. Conversely, strong CYP3A4 inhibitors increase itraconazole plasma concentrations. The interpatient variability in itraconazole pharmacokinetics due to CYP3A4 genetic polymorphism, food effects, and drug interactions is substantial, which is the primary rationale for therapeutic drug monitoring.37
Therapeutic Drug Monitoring. TDM is recommended for itraconazole therapy because of the high interpatient pharmacokinetic variability and the narrow exposure window between subtherapeutic concentrations (associated with treatment failure) and toxic concentrations (associated with adverse effects). Plasma itraconazole trough concentrations (measured at steady state, typically after 14 days of therapy) should be above 0.5 mcg/mL for prophylaxis and above 1.0 mcg/mL for treatment of invasive fungal infections. Both itraconazole and hydroxy-itraconazole are measured together by high-performance liquid chromatography (HPLC); some assays report combined concentrations while others report each separately, requiring careful interpretation. Levels above 10 mcg/mL are associated with increased toxicity including hepatotoxicity and congestive heart failure exacerbation. Itraconazole has a negative inotropic effect that can worsen or precipitate heart failure; it is contraindicated in patients with ventricular dysfunction and should be used with caution in patients with any cardiac disease.78
Capsules: Take with a full meal; avoid PPIs, H2RAs, and antacids (absorption falls dramatically without acid). Not suitable for achlorhydric patients. Oral solution: Take on an empty stomach (fasting); far less pH-dependent. Preferred for systemic infections. Both formulations: Check trough level after 14 days (target >1.0 mcg/mL for treatment). Avoid in heart failure (negative inotropic effect). Contraindicated with rifampin. IV formulation available but cyclodextrin vehicle accumulates in renal failure (avoid if CrCl <30 mL/min for IV).
Azole resistance has become one of the most clinically consequential problems in medical mycology. Unlike polyene resistance, which remains rare, azole resistance has emerged extensively in certain Candida species and increasingly in Aspergillus fumigatus, driven by prolonged antifungal exposure and, for Aspergillus, by environmental azole fungicide use. Three primary mechanisms account for the majority of azole resistance in clinical isolates: target site alteration (mutations in ERG11), drug efflux (upregulation of ABC [ATP-binding cassette] and MFS [major facilitator superfamily] transporters), and target bypass (ERG3 [C-5 sterol desaturase gene] mutations that alter the sterol substrate so that toxic sterol intermediates do not accumulate).
ERG11 Mutations and Target Site Alteration. Point mutations in the ERG11 gene encoding CYP51 (the azole target enzyme) reduce azole binding affinity by altering key amino acid residues that make contact with the azole triazole nitrogen or the adjacent side chain. Over 140 distinct point mutations in ERG11 have been described in azole-resistant Candida albicans clinical isolates, with certain hot-spot mutations at positions such as tyrosine-132 (Y132H), lysine-143 (K143R), phenylalanine-145 (F145L), and glycine-307 (G307S) conferring significant reductions in fluconazole susceptibility. ERG11 mutations generally confer resistance to fluconazole more readily than to voriconazole or itraconazole, because the additional hydrophobic contacts made by the extended side chains of the latter agents partially compensate for the loss of triazole nitrogen binding. In Aspergillus fumigatus, CYP51A (the Aspergillus CYP51 isoform) mutations at codon positions leucine-98 (L98H), glycine-54 (G54E/G54R), and glycine-138 (G138C/G138R) are the dominant resistance mechanisms, with the L98H mutation typically accompanied by a tandem repeat in the promoter region of CYP51A (TR34/L98H), a combination that has been associated with environmental azole fungicide exposure and has spread globally.9
Efflux Pump Upregulation. Two families of drug efflux transporters contribute to azole resistance in Candida species. The first consists of ABC (adenosine triphosphate-binding cassette) transporters CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2), which actively export azoles from the fungal cell, reducing intracellular drug concentration below the threshold needed for CYP51 inhibition. CDR1 and CDR2 overexpression is transcriptionally regulated by the zinc finger transcription factor Tac1p; gain-of-function mutations in TAC1 (the Tac1 transcription factor gene) constitutively upregulate CDR1 and CDR2, causing cross-resistance to fluconazole, itraconazole, and other azoles. The major facilitator superfamily (MFS) transporter Mdr1p (encoded by MDR1) provides a second efflux mechanism that is specific for fluconazole among the azoles; its overexpression is regulated by the transcription factor Mrr1p, and gain-of-function MRR1 (multidrug resistance regulator 1 gene) mutations constitutively activate MDR1 expression and confer fluconazole-specific resistance without necessarily affecting voriconazole or itraconazole susceptibility.210
ERG3 Mutations and Target Bypass. Mutations in ERG3, encoding C-5 sterol desaturase, provide a mechanism of azole resistance by altering the sterol product profile in the ergosterol biosynthesis pathway. Normally, azole inhibition of CYP51 causes accumulation of 14-alpha-methylfecosterol, which is toxic to the fungal cell and contributes to the antifungal effect. ERG3 mutations prevent the conversion of 14-alpha-methylfecosterol to the more toxic methylated sterol intermediates, reducing the toxic consequences of CYP51 inhibition and allowing the fungal cell to survive despite the presence of azole concentrations that would otherwise be inhibitory. ERG3 mutations are frequently found in combination with ERG11 mutations, creating high-level azole resistance. ERG3 mutations also confer resistance to polyenes by altering membrane ergosterol content, raising the clinical concern of sequential or combined polyene and azole resistance in heavily pre-treated patients.10
Clinical Epidemiology of Azole Resistance. Among Candida species causing bloodstream infections, azole resistance rates differ substantially by species. Candida albicans remains predominantly fluconazole-susceptible in most regions (resistance rates below 5% in most surveillance studies), though resistance has emerged in patients with HIV (human immunodeficiency virus) infection and oropharyngeal candidiasis who received prolonged fluconazole therapy. Candida glabrata has the highest rates of fluconazole resistance among common Candida species, with resistance rates of 10 to 30% in many centers driven primarily by CDR1 and CDR2 efflux pump upregulation and secondarily by ERG11 mutations; susceptibility dose-dependent (SDD) isolates are even more common, requiring higher fluconazole doses that approach toxic concentrations. Candida krusei is intrinsically resistant to fluconazole due to low-affinity CYP51 combined with CDR (Candida Drug Resistance) efflux pumps, and should never be treated with fluconazole regardless of susceptibility testing results.610
Candida albicans: Generally susceptible to fluconazole; test non-invasive isolates if prolonged prior azole exposure. Candida glabrata: Assume potential azole resistance; echinocandin preferred for invasive infections; fluconazole only if confirmed susceptible and stable patient. Candida krusei: Intrinsic fluconazole resistance; never use fluconazole. Candida auris: Variable pan-azole resistance; echinocandin is drug of choice; susceptibility testing mandatory. Aspergillus fumigatus: Test azole susceptibility in patients previously exposed to azoles or in geographic areas with high environmental resistance rates.
The drug interaction profile of azole antifungals is one of the most complex and consequential in all of clinical pharmacology. Understanding which cytochrome P450 (CYP) enzymes each azole inhibits, the magnitude of inhibition, and the clinical consequences for co-administered drugs is not optional knowledge for clinicians prescribing in transplant, oncology, HIV (human immunodeficiency virus), or intensive care settings, where azole-drug interactions can cause life-threatening toxicity or treatment failure.
CYP Inhibition Profiles. Fluconazole is a potent inhibitor of CYP2C9 (cytochrome P450 2C9) and a moderate inhibitor of CYP3A4 (cytochrome P450 3A4) and CYP2C19 (cytochrome P450 2C19). It does not significantly inhibit CYP1A2 (cytochrome P450 1A2) or CYP2D6 (cytochrome P450 2D6). Itraconazole is a potent inhibitor of CYP3A4 and P-glycoprotein (P-gp), a drug efflux transporter; it does not significantly inhibit CYP2C9 or CYP2C19. The distinction between fluconazole (primarily CYP2C9) and itraconazole (primarily CYP3A4) inhibition profiles means that the two agents, despite sharing a class mechanism, have largely different drug interaction liabilities. Clinicians must therefore look up interactions for each specific azole rather than generalizing across the class. Both agents inhibit hepatic and intestinal CYP enzymes, meaning interactions occur with orally administered substrates (where both pre-systemic and systemic metabolism are inhibited) as well as IV substrates (where only systemic metabolism is affected).3
Calcineurin Inhibitor Interactions. The interaction between azoles and calcineurin inhibitors (tacrolimus and cyclosporine) is among the most clinically consequential in transplant medicine. Tacrolimus is a CYP3A4 and P-gp substrate with an extremely narrow therapeutic index; itraconazole co-administration can increase tacrolimus blood concentrations by 5- to 10-fold or more, causing calcineurin inhibitor toxicity (nephrotoxicity, neurotoxicity, hypertension). Fluconazole causes a smaller but still clinically significant increase in tacrolimus concentrations (2- to 4-fold) through CYP3A4 inhibition. Cyclosporine concentrations are similarly increased by both agents. When initiating any azole in a transplant patient receiving calcineurin inhibitors, tacrolimus or cyclosporine doses must be proactively reduced (often by 50 to 75% for potent azoles) and trough concentrations monitored daily until a new steady state is achieved. Failure to do so is a preventable cause of serious transplant toxicity.311
Warfarin Interaction. Fluconazole significantly potentiates warfarin anticoagulation through CYP2C9 inhibition. CYP2C9 is the primary enzyme responsible for the metabolism of S-warfarin, the more pharmacologically active enantiomer; fluconazole inhibition of CYP2C9 reduces S-warfarin clearance and elevates the international normalized ratio (INR) substantially, with INR increases of 2- to 3-fold reported within days of initiating fluconazole. Itraconazole also interacts with warfarin, primarily through CYP3A4 inhibition of R-warfarin metabolism, though the magnitude is generally less than with fluconazole. Patients receiving warfarin who are started on any azole require close INR monitoring within 3 to 5 days of initiation, with dose reductions guided by INR response. Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban are CYP3A4 and P-gp substrates and are also affected by itraconazole (and other potent CYP3A4 inhibitor azoles), with plasma levels of these direct oral anticoagulants (DOACs) potentially increasing to hemorrhage-risk concentrations.3
Cardiac Repolarization Effects. Both fluconazole and itraconazole can prolong the corrected QT (QTc) interval on the electrocardiogram (ECG), reflecting ventricular repolarization duration), though by different mechanisms. Fluconazole directly blocks the hERG (human ether-a-go-go-related gene) cardiac potassium channel, causing dose-dependent QTc prolongation; clinically significant QTc prolongation and torsades de pointes have been reported, particularly at doses of 400 mg or above and in patients with additional risk factors (hypokalemia, hypomagnesemia, concurrent QT-prolonging drugs, baseline QTc prolongation, bradycardia, female sex). Itraconazole causes QTc prolongation both through direct hERG channel effects and indirectly by increasing plasma concentrations of co-administered QT-prolonging drugs via CYP3A4 inhibition. A baseline electrocardiogram (ECG) and electrolyte assessment are indicated before initiating azole therapy in high-risk patients, with ECG monitoring during prolonged courses at higher doses.11
Azole + tacrolimus/cyclosporine: Reduce calcineurin inhibitor dose 50–75% at azole initiation; monitor trough daily. Fluconazole + warfarin: INR check within 3–5 days; expect 2–3× INR increase; reduce warfarin dose proactively. Azole + statins (simvastatin, lovastatin): Contraindicated with itraconazole (potent CYP3A4 inhibitor → myopathy/rhabdomyolysis risk); use pravastatin or rosuvastatin instead. Azole + QT-prolonging drugs: Avoid combination or monitor ECG closely (antipsychotics, methadone, quinolones, macrolides). Itraconazole + rifampin: Essentially contraindicated; rifampin reduces itraconazole levels to near zero.
Fluconazole and itraconazole together cover a broad range of fungal infections but each has well-defined boundaries of appropriate use. Recognizing these boundaries, particularly when a broader-spectrum azole or a different antifungal class is required, is as important as knowing the indications for use. The following framework integrates pharmacological properties, spectrum, resistance risk, and interaction burden into actionable prescribing principles.
When Fluconazole Is Appropriate. Fluconazole is the first-line drug for oropharyngeal and esophageal candidiasis, uncomplicated vulvovaginal candidiasis, and cryptococcal meningitis consolidation and maintenance therapy. It is appropriate for step-down therapy in candidemia caused by Candida albicans, Candida tropicalis, or Candida parapsilosis after at least five to seven days of echinocandin induction, provided the patient is clinically stable, blood cultures are negative, and susceptibility has been confirmed. It is the agent of choice for antifungal prophylaxis in allogeneic hematopoietic stem cell transplant (HSCT) recipients during the engraftment period and in high-risk liver transplant recipients, where the predominant risk is from fluconazole-susceptible Candida species. Fluconazole is also appropriate for treatment of coccidioidomycosis (non-meningeal pulmonary and non-severe disseminated disease) at doses of 400 to 800 mg daily, given its superior central nervous system (CNS) penetration compared to itraconazole for meningeal coccidioidomycosis (where fluconazole 400 to 800 mg daily is the preferred long-term suppressive agent).36
When Itraconazole Is Appropriate. Itraconazole has a broader antifungal spectrum than fluconazole, adding reliable activity against Aspergillus species, Blastomyces dermatitidis, Histoplasma capsulatum, and Sporothrix schenckii. It is the drug of choice for mild to moderate histoplasmosis (including chronic pulmonary histoplasmosis and disseminated disease in non-immunocompromised patients who do not require amphotericin B induction), blastomycosis (non-CNS, non-severe pulmonary or disseminated disease), and sporotrichosis (lymphocutaneous and pulmonary forms). For dermatophyte onychomycosis, itraconazole pulse therapy (200 mg twice daily for one week per month for two to three months for fingernails, three months for toenails) is an alternative to terbinafine. The oral solution formulation is preferred over capsules for all systemic indications given more reliable absorption, and therapeutic drug monitoring (TDM) is recommended for invasive fungal infections to confirm therapeutic drug exposure.78
When to Escalate Beyond Fluconazole and Itraconazole. Neither fluconazole nor itraconazole is adequate for invasive aspergillosis (voriconazole or isavuconazole are first-line), mucormycosis (liposomal amphotericin B is first-line), or infections due to fluconazole-resistant Candida species. The extended-spectrum azoles (voriconazole, posaconazole, isavuconazole) should be chosen when the infecting organism is not covered by fluconazole or itraconazole, or when the infection site (CNS for itraconazole) or the interaction burden (high-dose itraconazole in a transplant patient) makes the available agents unsuitable. Echinocandins should be preferred over any azole for empirical treatment of candidemia in hospitalized patients, particularly those who are severely ill, have prior azole exposure, or are infected with Candida glabrata or unknown Candida species, pending susceptibility data. Deescalation to fluconazole is then appropriate once the organism is identified as susceptible and the patient is stable.56
Monitoring During Azole Therapy. Liver function tests (LFTs) including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase should be measured at baseline and periodically (every two to four weeks) during prolonged azole therapy. Hepatotoxicity occurs with all azoles but is most common with itraconazole and voriconazole; fluconazole hepatotoxicity is rare at standard doses. TDM is routinely recommended for itraconazole (target trough above 1.0 mcg/mL for treatment). Electrocardiogram (ECG) monitoring for QTc prolongation is appropriate in high-risk patients. Drug interaction review using a validated interaction database (not memory) should be performed at every azole initiation, and for calcineurin inhibitor-based immunosuppression, tacrolimus or cyclosporine trough concentrations must be monitored intensively during the first week of any azole start or dose change.311
Use fluconazole when: oral candidiasis, esophageal candidiasis, vulvovaginal candidiasis, cryptococcal consolidation/maintenance, candidemia step-down (susceptible species), HSCT/liver transplant prophylaxis, coccidioidomycosis. Use itraconazole when: histoplasmosis (mild-moderate), blastomycosis (non-CNS), sporotrichosis, onychomycosis, Aspergillus (non-severe, step-down). Do not use either when: invasive aspergillosis (use voriconazole/isavuconazole), mucormycosis (use L-AmB), C. krusei (intrinsic fluconazole resistance), C. auris (echinocandin preferred), CNS infections (avoid itraconazole), azole-resistant C. glabrata (use echinocandin).
Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272-279.
doi:10.1016/S0966-842X(03)00117-3Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73-85.
doi:10.1016/S1473-3099(02)00181-0Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
doi:10.1093/cid/civ933Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl 3):S318-S326.
doi:10.1093/clinids/12.supplement_3.s318Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis. 2001;32(8):1191-1200.
doi:10.1086/319763Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445-1456.
doi:10.1056/NEJMra1315399Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37(4):778-784.
doi:10.1128/AAC.37.4.778Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42(7-8):443-451.
doi:10.1046/j.1439-0507.1999.00505.xSnelders E, van der Lee HAL, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5(11):e219.
doi:10.1371/journal.pmed.0050219Carolus H, Pierson S, Lagrou K, Van Dijck P. Amphotericin B and other polyenes — discovery, clinical use, mode of action and drug resistance. J Fungi. 2020;6(4):321.
doi:10.3390/jof6040321Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441-1458.
doi:10.1086/598327